The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

NANot yet recruitingINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
FibromyalgiaPregabalinPain
Interventions
DRUG

Pregabalin

For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.

DRUG

Crisugabalin

For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.

Trial Locations (1)

Unknown

Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing

All Listed Sponsors
collaborator

China-Japan Friendship Hospital

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

Peking University Third Hospital

OTHER

collaborator

The Fourth Affiliated Hospital of Harbin Medical University

OTHER

collaborator

Zhongnan Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The Affiliated Hospital of Yanbian University

OTHER

lead

Beijing Tiantan Hospital

OTHER

NCT07196657 - The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia | Biotech Hunter | Biotech Hunter